Alpha 2.0
Login Register
» Authors » I A Mayer

I A Mayer

Explore the profile of I A Mayer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 435
Followers 0
Related Specialties
Oncology
Biochemistry
Hematology
Top 10 Co-Authors
E N Fish
B Majchrzak
L C Platanias
S E Nunnery
F Lekmine
D Juric
S Uddin
I M Grumbach
S Fujita
D Mills
Published In
Ann Oncol
Br J Haematol
J Biol Chem
Affiliations
Soon will be listed here.
Recent Articles
1.
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
Andre F, Ciruelos E, Juric D, Loibl S, Campone M, Mayer I, et al.
Ann Oncol . 2020 Nov; 32(2):208-217. PMID: 33246021
Background: Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancers (ABCs) and is associated...
2.
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
Kalinsky K, Diamond J, Vahdat L, Tolaney S, Juric D, OShaughnessy J, et al.
Ann Oncol . 2020 Sep; 31(12):1709-1718. PMID: 32946924
Background: Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC). Sacituzumab govitecan (SG; Trodelvy®) is an antibody-drug conjugate composed of a humanized...
3.
Management of toxicity to isoform α-specific PI3K inhibitors
Nunnery S, Mayer I
Ann Oncol . 2020 Jan; 30 Suppl 10:x21-x26. PMID: 31928691
Alterations in the phosphoinositide 3-kinase (PI3K)/AKT pathway are frequently found in cancer and are especially common in breast cancer, where it is estimated that 70% of tumors have some type...
4.
Management of toxicity to isoform α-specific PI3K inhibitors
Nunnery S, Mayer I
Ann Oncol . 2019 Oct; 30(Suppl_10):x21-x26. PMID: 31626273
Alterations in the phosphoinositide 3-kinase (PI3K)/AKT pathway are frequently found in cancer and are especially common in breast cancer, where it is estimated that 70% of tumors have some type...
5.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick A, et al.
Ann Oncol . 2019 Mar; 30(6):927-933. PMID: 30903140
Background: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2...
6.
The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells
Mayer I, Verma A, Grumbach I, Uddin S, Lekmine F, Ravandi F, et al.
J Biol Chem . 2001 May; 276(30):28570-7. PMID: 11353767
The mechanisms by which interferon-alpha (IFN-alpha) mediates its anti-leukemic effects in chronic myelogenous leukemia (CML) cells are not known. We determined whether p38 MAPK is activated by IFN-alpha in BCR-ABL-expressing...
7.
Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells
Grumbach I, Mayer I, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, et al.
Br J Haematol . 2001 Feb; 112(2):327-36. PMID: 11167825
Interferon alpha (IFNalpha) has significant clinical activity in the treatment of patients with chronic myelogenous leukaemia (CML), but the mechanisms of its selective efficacy in the treatment of the disease...